HRP20150513T1 - Novi polimorf - Google Patents
Novi polimorf Download PDFInfo
- Publication number
- HRP20150513T1 HRP20150513T1 HRP20150513TT HRP20150513T HRP20150513T1 HR P20150513 T1 HRP20150513 T1 HR P20150513T1 HR P20150513T T HRP20150513T T HR P20150513TT HR P20150513 T HRP20150513 T HR P20150513T HR P20150513 T1 HRP20150513 T1 HR P20150513T1
- Authority
- HR
- Croatia
- Prior art keywords
- solid form
- form according
- nocturia
- vasopressin
- solvate
- Prior art date
Links
- 239000007787 solid Substances 0.000 claims 11
- 102000000370 Vasopressin V2 receptors Human genes 0.000 claims 3
- 108050008930 Vasopressin V2 receptors Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 206010029446 nocturia Diseases 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 238000002329 infrared spectrum Methods 0.000 claims 2
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000028235 central diabetes insipidus Diseases 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Claims (11)
1. Čvrsti oblik 1-(2-metil-4-(2,3,4,5-tetrahidro-1-benzazepin-1-ilkarbonil)benzilkarbamoil)-1-prolin-N,N-dimetilamida, koji pokazuje najmanje slijedeće karakteristične XRF pikove difrakcije praha (Cu Kα zračenje, izraženo u stupnjevima 2θ) na približno 5.5, 10.9, 14.2, 21.9 i 24.0.
2. Čvrsti oblik prema zahtjevu 1 koji ima rendgenski difraktogram u suštini isti kao onaj prikazan na slici 1.
3. Čvrsti oblik prema zahtjevima 1 ili 2 naznačen IR spektrom koji ima pikove izraženo u cm-1 na približno 3525, 3425, 2932, 2873, 2135, 1958, 1925, 1631, 1529, 1489, 1439, 1377, 1355, 1311, 1260, 770, 743.
4. Čvrsti oblik prema bilo kojem od zahtjeva 1 do 3 koji ima IR spektar u suštini isti kao onaj prikazan na slici 3.
5. Čvrsti oblik prema bilo kojem od patentnih zahtjeva 1 do 4 koji je hidrat.
6. Čvrsti oblik prema zahtjevu 5, naznačen time što hidrat predstavlja monohidrat.
7. Farmaceutski sastav koji sadrži čvrsti oblik prema bilo kojem od zahtjeva 1 do 6, ili njegov solvat, zajedno sa farmaceutski prihvatljivim adjuvansom, diluentom ili nosačem.
8. Čvrsti oblik prema bilo kojem od zahtjeva 1 do 6, ili njegov solvat, za upotrebu u terapiji.
9. Čvrsti oblik prema bilo kojem od zahtjeva 1 do 6, ili njegov solvat, za upotrebu u liječenju bolesti ili stanja posredovanog vazopresin V2 receptorima.
10. Čvrsti oblik za upotrebu prema zahtjevu 9, naznačen time što je oboljenje ili stanje posredovano vazopresin V2 receptorima izabrano između noćnog mokrenja, nokturije, poliurije uslijed centralnog dijabetesa insipidusa, urinarne inkontinencije i poremećaja krvarenja.
11. Čvrsti oblik za upotrebu prema zahtjevu 9, naznačen time što je oboljenje ili stanje posredovano vazopresin V2 receptorima nokturija.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1005623.2A GB201005623D0 (en) | 2010-04-01 | 2010-04-01 | New polymorph |
| US34704810P | 2010-05-21 | 2010-05-21 | |
| PCT/GB2011/000500 WO2011121308A1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
| EP11714079.8A EP2552910B1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150513T1 true HRP20150513T1 (hr) | 2015-06-05 |
Family
ID=42228830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150513TT HRP20150513T1 (hr) | 2010-04-01 | 2015-05-13 | Novi polimorf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9079881B2 (hr) |
| EP (1) | EP2552910B1 (hr) |
| JP (1) | JP5802737B2 (hr) |
| KR (1) | KR101792621B1 (hr) |
| CN (1) | CN102918038B (hr) |
| CA (1) | CA2795109C (hr) |
| DK (1) | DK2552910T3 (hr) |
| ES (1) | ES2538085T3 (hr) |
| GB (1) | GB201005623D0 (hr) |
| HR (1) | HRP20150513T1 (hr) |
| HU (1) | HUE026442T2 (hr) |
| ME (1) | ME02102B (hr) |
| MX (1) | MX2012011382A (hr) |
| PL (1) | PL2552910T3 (hr) |
| PT (1) | PT2552910E (hr) |
| RS (1) | RS53956B1 (hr) |
| RU (1) | RU2559633C2 (hr) |
| SI (1) | SI2552910T1 (hr) |
| SM (1) | SMT201500107B (hr) |
| WO (1) | WO2011121308A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201105537D0 (en) | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| CN104059070B (zh) * | 2013-09-17 | 2016-02-10 | 天津药物研究院有限公司 | 利希普坦晶型ⅰ及其制备方法和用途 |
| CN103755707B (zh) * | 2013-09-17 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅱ及其制备方法和用途 |
| CN103694240B (zh) * | 2013-09-18 | 2015-11-18 | 天津药物研究院 | 利希普坦的溶剂合物及其制备方法和用途 |
| CN104140429B (zh) * | 2014-07-25 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅴ及其制备方法和用途 |
| JP7304043B2 (ja) | 2015-07-22 | 2023-07-06 | アナベックス ライフ サイエンシズ コーポレイション | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 |
| WO2020154581A1 (en) | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW359669B (en) | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
| DK1000059T3 (da) | 1997-07-30 | 2005-01-10 | Wyeth Corp | Tricycliske vasopressin-agonister |
| ATE277050T1 (de) | 1997-07-30 | 2004-10-15 | Wyeth Corp | Trizyclische vasopressin agoniste |
| CN1339035A (zh) | 1999-02-04 | 2002-03-06 | 美国家用产品公司 | 吡啶并苯并二吖庚因和吡啶并苯并氧杂吖庚因酰胺血管加压素激动剂 |
| ATE229528T1 (de) | 1999-02-04 | 2002-12-15 | Wyeth Corp | Pyrrolobenzodiazepine carboxamide vasopressin agonisten |
| PT1149096E (pt) | 1999-02-04 | 2003-03-31 | Wyeth Corp | N-oxidos de piridina triciclicos agonistas de vasopressina |
| CN1339036A (zh) | 1999-02-04 | 2002-03-06 | 美国家用产品公司 | 作为血管加压素激动剂的噻吩基苯甲酰基苯并吖庚因 |
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
-
2010
- 2010-04-01 GB GBGB1005623.2A patent/GB201005623D0/en not_active Ceased
-
2011
- 2011-03-31 WO PCT/GB2011/000500 patent/WO2011121308A1/en active Application Filing
- 2011-03-31 RS RS20150258A patent/RS53956B1/en unknown
- 2011-03-31 JP JP2013501934A patent/JP5802737B2/ja not_active Expired - Fee Related
- 2011-03-31 RU RU2012146544/04A patent/RU2559633C2/ru not_active IP Right Cessation
- 2011-03-31 KR KR1020127028111A patent/KR101792621B1/ko active IP Right Grant
- 2011-03-31 DK DK11714079T patent/DK2552910T3/en active
- 2011-03-31 PT PT117140798T patent/PT2552910E/pt unknown
- 2011-03-31 MX MX2012011382A patent/MX2012011382A/es active IP Right Grant
- 2011-03-31 ME MEP-2015-56A patent/ME02102B/me unknown
- 2011-03-31 CA CA2795109A patent/CA2795109C/en not_active Expired - Fee Related
- 2011-03-31 HU HUE11714079A patent/HUE026442T2/en unknown
- 2011-03-31 US US13/637,873 patent/US9079881B2/en not_active Expired - Fee Related
- 2011-03-31 ES ES11714079.8T patent/ES2538085T3/es active Active
- 2011-03-31 SI SI201130487T patent/SI2552910T1/sl unknown
- 2011-03-31 EP EP11714079.8A patent/EP2552910B1/en active Active
- 2011-03-31 PL PL11714079T patent/PL2552910T3/pl unknown
- 2011-03-31 CN CN201180026714.4A patent/CN102918038B/zh not_active Expired - Fee Related
-
2015
- 2015-05-05 SM SM201500107T patent/SMT201500107B/xx unknown
- 2015-05-13 HR HRP20150513TT patent/HRP20150513T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013523706A (ja) | 2013-06-17 |
| ME02102B (me) | 2015-10-20 |
| RS53956B1 (en) | 2015-08-31 |
| EP2552910B1 (en) | 2015-03-11 |
| HUE026442T2 (en) | 2016-06-28 |
| CA2795109C (en) | 2018-04-17 |
| EP2552910A1 (en) | 2013-02-06 |
| US9079881B2 (en) | 2015-07-14 |
| WO2011121308A1 (en) | 2011-10-06 |
| KR101792621B1 (ko) | 2017-11-02 |
| US20140296213A1 (en) | 2014-10-02 |
| GB201005623D0 (en) | 2010-05-19 |
| MX2012011382A (es) | 2013-01-29 |
| CN102918038A (zh) | 2013-02-06 |
| CA2795109A1 (en) | 2011-10-06 |
| ES2538085T3 (es) | 2015-06-17 |
| KR20130023218A (ko) | 2013-03-07 |
| JP5802737B2 (ja) | 2015-11-04 |
| DK2552910T3 (en) | 2015-04-07 |
| PL2552910T3 (pl) | 2015-07-31 |
| PT2552910E (pt) | 2015-05-13 |
| RU2012146544A (ru) | 2014-05-10 |
| RU2559633C2 (ru) | 2015-08-10 |
| SI2552910T1 (sl) | 2015-06-30 |
| SMT201500107B (it) | 2015-07-09 |
| CN102918038B (zh) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150513T1 (hr) | Novi polimorf | |
| IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| PL2054411T3 (pl) | Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne | |
| JP2014162794A5 (hr) | ||
| MX351368B (es) | Compuestos heteroarilo y metodos para utilizarlos. | |
| PH12015500460A1 (en) | Coated pharmaceutical composition containing regorafenib | |
| NZ603043A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
| IL222993A (en) | Their compounds and preparations for the treatment of sclerosis, inflammatory disease and other disorders | |
| WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
| HRP20192132T1 (hr) | Antagonist nk-1/nk-3 receptora za liječenje valunga | |
| JP2013522326A5 (hr) | ||
| NZ605431A (en) | D2 antagonists, methods of synthesis and methods of use | |
| JP2013515006A5 (hr) | ||
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| JP2014530818A5 (hr) | ||
| MX356105B (es) | Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida. | |
| EP2238105A4 (en) | NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
| AU2012277905A8 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| EA201101207A1 (ru) | Применение антагонистов рецептора nk | |
| EP2195036A4 (en) | COMPOSITIONS FOR THE TREATMENT OF TUMORS BY DIRECT ADMINISTRATION OF A RADIO ISOTOPE | |
| FR3007983B1 (fr) | Association de xenon et d'un antagoniste des recepteurs nmda pour lutter contre une maladie neurodegenerative | |
| EP2633312A4 (en) | REAL-TIME MONITORING SOLID PHASE PEPTIDE SYNTHESIS BY MASS SPECTROMETRY | |
| EA201790072A1 (ru) | Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы |